Birmingham Women's and Children's Hospital, NHS Foundation Trust, Birmingham B4 6NH, UK.
Department of Paediatrics and Adolescent Medicine, Johannes Kepler University, Kepler University Hospital, Krankenhausstraße 26-30, 4020 Linz, Austria.
Nutrients. 2021 Apr 16;13(4):1323. doi: 10.3390/nu13041323.
Protein quality and quantity are important factors in determining lean body (muscle) mass (LBM). In phenylketonuria (PKU), protein substitutes provide most of the nitrogen, either as amino acids (AA) or glycomacropeptide with supplementary amino acids (CGMP-AA). Body composition and growth are important indicators of long-term health. In a 3-year prospective study comparing the impact of AA and CGMP-AA on body composition and growth in PKU, 48 children were recruited. = 19 (median age 11.1 years, range 5-15 years) took AA only, = 16 (median age 7.3 years, range 5-15 years) took a combination of CGMP-AA and AA, (CGMP50) and 13 children (median age 9.2 years, range 5-16 years) took CGMP-AA only (CGMP100). A dual energy X-ray absorptiometry (DXA) scan at enrolment and 36 months measured LBM, % body fat (%BF) and fat mass (FM). Height was measured at enrolment, 12, 24 and 36 months. No correlation or statistically significant differences (after adjusting for age, gender, puberty and phenylalanine blood concentrations) were found between the three groups for LBM, %BF, FM and height. The change in height z scores, (AA 0, CGMP50 +0.4 and CGMP100 +0.7) showed a trend that children in the CGMP100 group were taller, had improved LBM with decreased FM and % BF but this was not statistically significant. There appeared to be no advantage of CGMP-AA compared to AA on body composition after 3-years of follow-up. Although statistically significant differences were not reached, a trend towards improved body composition was observed with CGMP-AA when it provided the entire protein substitute requirement.
蛋白质的质量和数量是决定瘦体(肌肉)质量(LBM)的重要因素。在苯丙酮尿症(PKU)中,蛋白质替代品提供了大部分氮,要么是氨基酸(AA),要么是含有补充氨基酸的糖巨肽(CGMP-AA)。身体成分和生长是长期健康的重要指标。在一项为期 3 年的前瞻性研究中,比较了 AA 和 CGMP-AA 对 PKU 患者身体成分和生长的影响,招募了 48 名儿童。19 名(中位数年龄 11.1 岁,范围 5-15 岁)仅服用 AA,16 名(中位数年龄 7.3 岁,范围 5-15 岁)服用 CGMP-AA 和 AA 的组合(CGMP50),13 名儿童(中位数年龄 9.2 岁,范围 5-16 岁)仅服用 CGMP-AA(CGMP100)。在入组时和 36 个月时进行双能 X 射线吸收法(DXA)扫描,测量瘦体质量、体脂肪百分比(%BF)和脂肪量(FM)。身高在入组时、12、24 和 36 个月时测量。在三组之间,LBM、%BF、FM 和身高之间没有相关性或统计学上的显著差异(在调整年龄、性别、青春期和苯丙氨酸血浓度后)。身高 z 分数的变化(AA 为 0、CGMP50+0.4 和 CGMP100+0.7)显示出一种趋势,即 CGMP100 组的儿童更高,LBM 增加,FM 和% BF 减少,但这没有统计学意义。在 3 年的随访后,CGMP-AA 与 AA 相比,在身体成分方面似乎没有优势。尽管未达到统计学显著差异,但随着 CGMP-AA 提供了整个蛋白质替代物的需求,观察到身体成分有改善的趋势。